Literature DB >> 10582348

New insights into the roles of ReL/NF-kappa B transcription factors in immune function, hemopoiesis and human disease.

M Grossmann1, Y Nakamura, R Grumont, S Gerondakis.   

Abstract

In mammals, Rel/NF-kappa B proteins are a small family of transcription factors which serve as pivotal regulators of immune, inflammatory and acute phase responses. Pathways leading to the activation of Rel/NF-kappa B have recently been dissected in some detail and shown to converge on a unique high molecular weight cytoplasmic complex that includes several kinases and regulatory molecules. Moreover, gene targeting experiments have identified novel roles for Rel/NF-kappa B proteins in the development and maturation of hemopoietic precursors as well as in the function of mature cells in the immune system. These include regulating the cell cycle, controlling cell survival and providing a link between the innate and adaptive immune systems. Since the dysregulation of Rel/NF-kappa B function is associated with various pathologies including inflammatory and neoplastic disease, new insights into the role of Rel/NF-kappa B in human disease may provide a basis for therapeutic strategies in the treatment of chronic inflammatory diseases and certain malignancies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10582348     DOI: 10.1016/s1357-2725(99)00068-0

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  24 in total

1.  A novel interferon regulatory factor (IRF), IRF-10, has a unique role in immune defense and is induced by the v-Rel oncoprotein.

Authors:  Jirí Nehyba; Radmila Hrdlicková; Joan Burnside; Henry R Bose
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

Review 2.  VEGF as a mediator of tumor-associated immunodeficiency.

Authors:  J E Ohm; D P Carbone
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

3.  Lung-targeted overexpression of the NF-κB member RelB inhibits cigarette smoke-induced inflammation.

Authors:  David H McMillan; Carolyn J Baglole; Thomas H Thatcher; Sanjay Maggirwar; Patricia J Sime; Richard P Phipps
Journal:  Am J Pathol       Date:  2011-05-05       Impact factor: 4.307

4.  Ocular fibroblast diversity: implications for inflammation and ocular wound healing.

Authors:  Xia Xi; David H McMillan; Geniece M Lehmann; Patricia J Sime; Richard T Libby; Krystel R Huxlin; Steven E Feldon; Richard P Phipps
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-01       Impact factor: 4.799

5.  Cell-specific association and shuttling of IkappaBalpha provides a mechanism for nuclear NF-kappaB in B lymphocytes.

Authors:  W F Tam; W Wang; R Sen
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

6.  Anti-rheumatic drug iguratimod (T-614) alleviates cancer-induced bone destruction via down-regulating interleukin-6 production in a nuclear factor-κB-dependent manner.

Authors:  Yue Sun; Da-Wei Ye; Peng Zhang; Ying-Xing Wu; Bang-Yan Wang; Guang Peng; Shi-Ying Yu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

7.  The aryl hydrocarbon receptor attenuates tobacco smoke-induced cyclooxygenase-2 and prostaglandin production in lung fibroblasts through regulation of the NF-kappaB family member RelB.

Authors:  Carolyn J Baglole; Sanjay B Maggirwar; Thomas A Gasiewicz; Thomas H Thatcher; Richard P Phipps; Patricia J Sime
Journal:  J Biol Chem       Date:  2008-08-12       Impact factor: 5.157

Review 8.  Promising personalized therapeutic options for diffuse large B-cell Lymphoma Subtypes with oncogene addictions.

Authors:  James J Steinhardt; Ronald B Gartenhaus
Journal:  Clin Cancer Res       Date:  2012-06-27       Impact factor: 12.531

9.  JFC1 is transcriptionally activated by nuclear factor-kappaB and up-regulated by tumour necrosis factor alpha in prostate carcinoma cells.

Authors:  Sergio D Catz; Bernard M Babior; Jennifer L Johnson
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

10.  Protective effects of leflunomide on intestinal ischemia-reperfusion injury: leflunomide against intestinal ischemia-reperfusion.

Authors:  Yuksel Yildiz; Hayrullah Kose; Serpil Cecen; Kemal Ergin; Ece Mine Demir; Mukadder Serter
Journal:  Dig Dis Sci       Date:  2009-02-20       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.